pharma · Microcystic Lymphatic Malformation · Pachyonychia Congenita · PVLA
PALVELLA THERAPEUTICS
PALVELLA THERAPEUTICS, INC.
PALVELLA THERAPEUTICS clinical programs — 7 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- Wayne, USA
- Founded
- 2015
- Employees
- 38
- Programs
- 7
- Drugs
- 0
- Patents
- 9
PALVELLA THERAPEUTICS projects
7 ClinicalTrials.gov programs sponsored by PALVELLA THERAPEUTICS.
PALVELLA THERAPEUTICS has 7 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
PTX-022
PALVELLA THERAPEUTICS, INC.
Pachyonychia Congenita
3 trials -
QTORIN 3.9% Rapamycin Anhydrous Gel
PALVELLA THERAPEUTICS, INC.
Microcystic Lymphatic Malformation
1 trial -
QTORIN 3.9% rapamycin anhydrous gel
PALVELLA THERAPEUTICS, INC.
Pachyonychia Congenita
1 trial -
PTX-022
PALVELLA THERAPEUTICS, INC.
BCCs in Gorlin Syndrome Patients
1 trial -
PTX-022
PALVELLA THERAPEUTICS, INC.
Microcystic Lymphatic Malformation
1 trial -
PTX-022
PALVELLA THERAPEUTICS, INC.
Angiokeratomas
1 trial -
QTORIN 3.9% rapamycin anhydrous gel
PALVELLA THERAPEUTICS, INC.
Cutaneous Venous Malformations
1 trial
Frequently asked questions
How many clinical projects does PALVELLA THERAPEUTICS have?
7 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.